Patent ID: 8642082
Filing Date: 2014-02-04
Classification: A61K,A61P

Abstract:
1. An oral pharmaceutical composition for the controlled release of heparin or a derivative thereof, consisting essentially of: a) a lipophilic/amphiphilic matrix consisting of amphiphilic compounds and lipophilic compounds with a melting point lower than 90° C. in which the heparin or derivative thereof is at least partially dispersed, said amphiphilic compounds being selected from polar lipids of type I or II, glycol alkyl ethers, polyoxyethylenated castor oil, polysorbates, phosphoacetylcholine, sodium laurylsulfate, fatty acids sucroesters and polyethylene glycols; b) a hydrophilic matrix in which the lipophilic/amphiphilic matrix is dispersed; c) other excipients suitable for solid pharmaceutical forms; and d) a gastro-resistant coating; wherein the heparin or derivative thereof is dispersed both in the hydrophilic matrix and in the lipophilic/amphiphilic matrix; wherein the oral composition is in the form of tablets, capsules or mini-matrices; and wherein the dosage range of heparin or derivative thereof is 5-1000 mg per single dose.